Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Search
SEMINTRA® (Telmisartan Oral Solution) | Boehringer Ingelheim US
Introducing SEMINTRA® (telmisartan oral solution) —The first FDA-approved liquid solution for the control of systemic feline hypertension.
Boehringer welcomes 2023 Gold Report
Boehringer welcomes 2023 GOLD Report Positioning LAMA/LABA as preferred treatment
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Cardiologists at the Heart of Cardio-Renal-Metabolic Care | Boehringer Ingelheim US
Cardiologists at the Heart of Cardio-Renal-Metabolic Care
Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US
Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.
US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch
US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)
Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients
Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients
Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
Interchangeable Biosimilar Now on Express Scripts® Formulary
Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary
Low-WAC interchangeable biosimilar is now available
Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.
Heart Failure
Heart Failure
Internal application
Internal applications | FAQ
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Brigitte Fuhr
Brigitte Fuhr, Head of Central Data Science, is working on a global program that will transform our ability to develop breakthrough treatments.
New agreement with Quallent expands biosimilar access
Boehringer Ingelheim enters private label agreement for biosimilar
More Green | Sustainable Development
Our MORE GREEN pillar encompasses initiatives that consider many different aspects: adopting measures to avoid water and air pollution, & much more.
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.
FDA approves additional formulation of biosimilar
US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.
Online application
Online application | FAQ
Lung Diseases
Our Therapeutic Areas